1 week ago
Cancer Vaccine Trial Raises Hopes for Treatment Beyond Melanoma
Scientists tested a vaccine called intismeran against melanoma, a type of skin cancer.
The trial was reported as successful on August 19.
Reports said the vaccine helped stop the cancer from returning.
This caused excitement about a possible new way to treat cancer.
Moderna’s shares reportedly more than doubled after the news.
Merck was also mentioned in headlines about the development.
However, it is not yet clear whether the vaccine will work for many other cancers.
The result may be an important breakthrough, but it could also be limited to melanoma.
A trial of intismeran, a vaccine for melanoma, was reported as successful on August 19.
The vaccine was described as stopping melanoma from returning in the trial.
Headlines called the development a breakthrough in cancer treatment.
Moderna shares reportedly more than doubled after news of the vaccine’s success.
The key question is whether the result applies broadly to other cancers or is a one-off.
- Who
- Researchers testing intismeran, with Moderna and Merck mentioned in coverage.
- What
- A trial reportedly found success for a vaccine intended to prevent melanoma from returning.
- Where
- When
- August 19; the year is not specified.
- Why
- The result raised hopes that vaccines could become a broader way to treat cancer.
Key facts
- Vaccine
- Intismeran
- Cancer type
- Melanoma, a skin cancer
- Trial result
- Reported as successful, with headlines saying it stopped cancer from returning
- Reported date
- August 19; year not specified
- Companies mentioned
- Moderna and Merck
- Main uncertainty
- Whether the result applies to cancers generally or is a one-off
Sources
Related news
Moderna-Merck Cancer Vaccine Shows Breakthrough in Melanoma Trial
Merck-Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk in Trial
Personalized mRNA Vaccine Shows Promise Against Melanoma Recurrence
Moderna Cancer Vaccine Shows Promise in Advanced Melanoma Trial
Moderna Shares Surge After Positive Personalized Melanoma Trial Results
Merck and Moderna Vaccine Posts Positive Phase 3 Melanoma Results
Moderna Cancer Vaccine Shows Early Melanoma Recurrence Benefits
Personalised cancer vaccine halves melanoma death risk in trial
